Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/38941
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMorrison, J. M.-
dc.contributor.authorHowell, A.-
dc.contributor.authorKelly, K. A.-
dc.contributor.authorGrieve, R. J.-
dc.contributor.authorMonypenny, I. J.-
dc.contributor.authorWalker, R. A.-
dc.contributor.authorWaterhouse, J. A. H .-
dc.date.accessioned2016-12-14T16:25:56Z-
dc.date.available2016-12-14T16:25:56Z-
dc.date.issued1989-12-
dc.identifier.citationBritish Journal of Cancer (1989) 60, 911–918.en
dc.identifier.issn1532-1827-
dc.identifier.issn0007-0920-
dc.identifier.urihttp://www.nature.com/bjc/journal/v60/n6/abs/bjc1989389a.htmlen
dc.identifier.urihttp://hdl.handle.net/2381/38941-
dc.description.abstractThe aim of this study was to test the effectiveness of a regimen of combination chemotherapy known to be active in advanced breast cancer when given as an adjuvant treatment after mastectomy. A total of 569 patients with cancer of the breast and involvement of axillary lymph nodes were randomised, after simple mastectomy with axillary sampling, to receive either no adjuvant treatment or intravenous adriamycin 50 mg, vincristine 1 mg, cyclophosphamide 250 mg, methotrexate 150 mg and fluorouracil 250 mg (AVCMF) every 21 days for eight cycles. Randomisation was stratified according to menopausal status and tumour size. Treatment was started within 14 days of surgery in 94% of patients. Eighty-eight per cent of patients received at least seven cycles of chemotherapy with no dose reduction. The median relapse-free survival was prolonged by 14 months in patients treated with AVCMF (chi2 1 = 11.7; P = 0.0006). In the premenopausal group this period was 17 months (chi2 1 = 8.8; P = 0.003) compared with 8 months in the post-menopausal group (chi2 1 = 3.3; P = 0.07). Neither overall survival nor survival in these subgroups was significantly influenced by treatment.en
dc.description.sponsorshipWe wish to thank the Cancer Research Campaign for grants to the project, Eli Lilly, Farmitalia Carlo Erba and Lederle for their financial assistance and also the Lions Club International District 105 and the many other groups and individuals within the West Midlands who provided support by fund raising activities or donation. In particular, we thank Lady Veronica Booth for working so hard as patron of our local fund raising campaign.en
dc.language.isoenen
dc.publisherCancer Research UK, Nature Publishing Groupen
dc.rightsCreative Commons “Attribution Non-Commercial No Derivatives” licence CC BY-NC-ND, further details of which can be found via the following link: http://creativecommons.org/licenses/by-nc-nd/4.0/ Archived with reference to SHERPA/RoMEO and publisher website.en
dc.titleWest Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodesen
dc.typeJournal Articleen
dc.identifier.doi10.1038/bjc.1989.389-
dc.description.statusPeer-revieweden
dc.description.versionPublisher Versionen
dc.type.subtypeArticle-
pubs.organisational-group/Organisationen
pubs.organisational-group/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGYen
pubs.organisational-group/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicineen
pubs.organisational-group/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cancer Studies and Molecular Medicineen
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
bjc1989389a.pdfPublished (publisher PDF)1.36 MBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.